Abstract
Background and Objectives
Use of proton pump inhibitor (PPI) in patients with cirrhosis has been linked to the development of hepatic encephalopathy (HE). Little is known about the incidence rate of HE due to PPI therapy. We conducted a meta-analysis to explore the association between PPI use and the incidence of HE.
Methods
We searched PubMed, EMBASE databases and The Cochrane Library from inception to March 2019 for studies describing the association between PPI exposure and incidence of HE; we identified studies that provided the adjusted estimates of odds ratio (OR)/relative ratio (RR)/hazard ratio (HR), and the pooled RRs on the incidence of HE were calculated. Summary estimates were calculated using random effects models.
Results
We analyzed data from 10 eligible studies; PPI users had an increased risk of HE compared with non-PPI user, with a pooled RR of 1.81 (95% CI 1.58–2.06), with notable heterogeneity (I2 = 85.2%, p <0.0001). In subgroup of considering the incidence of HE after yrans-jugular intrahepatic portosystemic shunt (TIPS), the pooled RR was 3.09 (95% CI 2.23–4.27), with no statistical heterogeneity (I2 = 0.0%, p = 0.484); another subgroup analysis was conducted for the complication of the enrolled patients with the status of ascites, the pooled RR was 1.39 (95% CI 1.10–1.77). The result of statistical heterogeneity was low (I2 = 46.2%, p = 0.156).
Conclusions
We found PPI therapy increased the risk of HE in cirrhotic patients, and higher risk was found in post-operative TIPS. Additional studies are warranted to inform clinical decision making.
Similar content being viewed by others
References
Wijdicks EFM. Hepatic encephalopathy. N Engl J Med. 2016;375:1660–70.
Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51:1675–82.
Zhu J, Qi X, Yu H, et al. Acid suppression in patients treated with endoscopic therapy for the management of gastroesophageal varices: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;2018(17474124):1456918.
Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14:697–710.
Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol. 2012;9:132–9.
Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176:172–4.
Zhu J, Yu H, Mancuso A, Qi X. Proton pump inhibitors in liver cirrhosis: a review of benefits and harms. AME Med J. 2017;2:36.
Deshpande A, Pasupuleti V, Thota P, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28:235–42.
Tsai CF, Chen MH, Wang YP, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology. 2017;152:134–41.
Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–8.
Reddymasu SC, Sostarich S, Mccallum RW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterol. 2010;10:23.
O’Leary JG, Reddy KR, Wong F, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13(753–9):e2.
Min YW, Lim KS, Min BH, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther. 2014;40:695–704.
Ratelle M, Perreault S, Villeneuve JP, et al. Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can J Gastroenterol Hepatol. 2016;28:330–4.
Bian J, Wang A, Lin J, et al. Association between proton pump inhibitors and hepatic encephalopathy. Medicine (Baltimore). 2017;96:e6723.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions (version 5.0.1). London: The Cochrane Collaboration; 2011.
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.
Wells GA, Shea B, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses [EB/OL]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed 30 Mar 2019.
Rostom A, Dube C, Cranney A, et al. Celiac disease. Rockville (MD): agency for healthcare research and quality (US); 2004 Sep. (Evidence Reports/Technology Assessments, No. 104.) Appendix D. Quality assessment forms. http://www.ncbi.nlm.nih.gov/books/NBK35156. Accessed 30 Mar 2019.
Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690–1.
Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715–35.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
Begg C, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
Lewis DS, Lee TH, Konanur M, et al. Proton pump inhibitor use is associated with an increased frequency of new or worsening hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol. 2019;30:163–9.
Sturm L, Bettinger D, Giesler M, et al. Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS). United Eur Gastroenterol J. 2018;6:1380–90.
Nardelli S, Gioia S, Ridola L, et al. Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics. Hepatology. 2018. https://doi.org/10.1002/hep.30304 (In press).
Tergast TL, Wranke A, Laser H, et al. Dose dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. Liver Int. 2018;38:1602–13.
Shanab AA, Smith A, Abbas M, et al. Proton pump inhibitors-a risk factor for hepatic encephalopathy in patients listed for liver transplantation? Hepatology. 2018;68:1176A.
Tapper EB, Henderson J, Baki J, et al. Incidence and predictors of hepatic encephalopathy in a population-based cohort of older Americans with cirrhosis: role of opiates, benzodiazepines and proton-pump inhibitors (PPIs). Hepatology. 2018;68:138A.
Dam G, Vilstrup H, Watson H, et al. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis patients with ascites. Hepatology. 2016;64:1265–72.
Zhu J, Qi X, Yu H, et al. Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis. United Eur Gastroenterol J. 2018;6:1179–87.
Matei D, Pasca S, David A, et al. Proton pump inhibitors increase the risk for hepatic encephalopathy in patients with cirrhosis and ascites. J Hepatol. 2017;66:S136.
Weersink RA, Bouma M, Burger DM, et al. Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018;84:1806–20.
Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706–15.
Dhanasekaran R, West JK, Gonzales PC, et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol. 2010;105:635–41.
Kikolski SG, Aryafar H, Rose SC, et al. Transjugular intrahepatic portosystemic shunt for treatment of cirrhosis-related chylothorax and chylous ascites: single-institution retrospective experience. Cardiovasc Interv Radiol. 2013;36:992–7.
Garcia-Pagan JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362:2370–9.
Bonnel AR, Bunchorntavakul C, Rajender Reddy K. Transjugular intrahepatic portosystemic shunts in liver transplant recipients. Liver Transpl. 2014;20:130–9.
Huang KW, Kuan YC, Luo JC, et al. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. Eur J Intern Med. 2016;32:91–5.
Acknowledgements
The authors are very grateful to all staffs of the Department of Pharmacy at First Affiliated Hospital of Wenzhou Medical University and Department of Anesthesiology at Second Affiliated Hospital of Wenzhou Medical University.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Funding
No sources of funding were received for the preparation of this study.
Conflict of interest
Dawei Shi, Ziye Zhou, Ying Dai, Xiaofeng Pan, Qinqin Cao have no conflicts of interest that are directly relevant to the content of this systematic review and meta-analysis.
Authorship
Guarantor of the article: Dawei Shi.
Author contributions
DS and ZZ designed the study, then screened titles and abstracts resulting from the search. YD and QC involved in the data extraction. DS performed the statistical analysis, interpreted the results and wrote the draft. XP helped with language editing and critically revised the manuscript.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Shi, D., Zhou, Z., Dai, Y. et al. Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis. Clin Drug Investig 39, 847–856 (2019). https://doi.org/10.1007/s40261-019-00810-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-019-00810-8